Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: An in vivo study

Thrombosis Journal

Volumn 7, Issue , 2009, Pages 14-

  Artang, Ramin ^a,b   Frandsen, Niels J ^a   Nielsen, Jørn D ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Mercy Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN;

ADULT; ANALYTIC METHOD; ANTITHROMBOTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MONITORING; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; REACTION TIME; SENSITIVITY AND SPECIFICITY; THROMBODYNAMIC RATIO; THROMBOELASTOGRAPHY;

EID: 70749114466     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-7-14     Document Type: Article

References (21)

1. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Lancet 1996, 347:561-568.
2. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997, 96:61-68.
3. Long-term low-molecular-mass heparin in unstable coronary- artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. FRISC II Investigators. Lancet 1999, 354:701-707. 10.1016/S0140-6736(99)07350-X, 10475180.
4. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-eight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997, 337:447-452. 10.1056/NEJM199708143370702, 9250846.
5. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999, 100:1593-1601.
6. Moliterno DJ, Mukherjee D. Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine. Am Heart J 2000, 140(6 suppl):S136-S142. 10.1067/mhj.2000.111608, 11100007.
7. Backe SK, Lyons GR. High-dose tinzaparin in pregnancy and the need for urgent delivery. Br J Anaesth 2002, 89:331-334. 10.1093/bja/aef189, 12378675.
8. Hartert H, Schaeder JA. The physical and biological constants of thrombelastography. Biorheolgy 1962, 1:31-39.
9. Chandler WL. The thromboelastography and the thromboelastograph technique. Semin Thromb Hemost 1995, 21(suppl 4):1-6.
10. Zuckerman L, Cohen E, Vagher JP, Woodward E, Caprini JA. Comparison of thrombelastography with common coagulation tests. Thromb Haemost 1981, 46:752-756.
11. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW, Starzl TE, Winter PM. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985, 64:888-896. 10.1213/00000539-198509000-00008, 3896028.
12. Spiess BD, Tuman KJ, McCarthy RJ, DeLaria GA, Schillo R, Ivankovich AD. Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies. J Clin Monit 1987, 3:25-30. 10.1007/BF00770880, 3819793.
13. Traverso CI, Caprini JA, Arcelus JI, Arcelus IM. Thromboelastographic modifications induced by intravenous and subcutaneous heparin administration. Semin Thromb Hemost 1995, 21(suppl 4):53-58.
14. Shinoda T, Arakura H, Katakura M, Shirota T, Nakagawa S. Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis. Artif Organs 1990, 14:413-415. 10.1111/j.1525-1594.1990.tb02996.x, 2177970.
15. Zmuda K, Neofotistos D, Ts'ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol 2000, 113:725-731. 10.1309/Q4AE-BMCW-CQ7J-NUVT, 10800406.
16. Klein SM, Slaughter TF, Vail PT, Ginsberg B, El-Moalem HE, Alexander R, D'Ercole F, Greengrass RA, Perumal TT, Welsby I, Gan TJ. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesth Analg 2000, 91:1091-1095. 10.1097/00000539-200011000-00009, 11049889.
17. Carroll RC, Craft RM, Whitaker GL, Snider CC, Kirby RK, Elder RF, Hennessey MD. Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients. Thromb Res 2007, 120:367-70. 10.1016/j.thromres.2006.10.011, 17150243.
18. Artang R, Jensen E, Pedersen F, Frandsen NJ. Thrombelastography in healthy volunteers, patients with stable angina and acute chest pain. Thromb Res 2000, 97:499-503. 10.1016/S0049-3848(99)00210-8, 10704661.
19. Traverso CI, Arcelus JI, Caprini JA. Role of thromboelastography in evaluating other anticoagulant agents: warfarin and heparin-dihydroergotamine. Semin Thromb Hemost 1995, 21(suppl 4):59-62.
20. Orlikowski CE, Payne AJ, Moodley J, Rocke DA. Thrombelastography after aspirin ingestion in pregnant and non-pregnant subjects. Br J Anaesth 1992, 69:159-161. 10.1093/bja/69.2.159, 1389819.
21. Arcelus JI, Traverso CI, Caprini JA. Thromboelastography for the assessment of hypercoagulability during general surgery. Semin Thromb Hemost 1995, 21(Suppl 4):21-6.